Literature DB >> 11702050

Kinetic analysis of [(11)C]MP4A using a high-radioactivity brain region that represents an integrated input function for measurement of cerebral acetylcholinesterase activity without arterial blood sampling.

S Nagatsuka Si1, K Fukushi, H Shinotoh, H Namba, M Iyo, N Tanaka, A Aotsuka, T Ota, S Tanada, T Irie.   

Abstract

N -[(11)C]methylpiperidin-4-yl acetate ([(11)C]MP4A) is an acetylcholine analog. It has been used successfully for the quantitative measurement of acetylcholinesterase (AChE) activity in the human brain with positron emission tomography (PET). [(11)C]MP4A is specifically hydrolyzed by AChE in the brain to a hydrophilic metabolite, which is irreversibly trapped locally in the brain. The authors propose a new method of kinetic analysis of brain AChE activity by PET without arterial blood sampling, that is, reference tissue-based linear least squares (RLS) analysis. In this method, cerebellum or striatum is used as a reference tissue. These regions, because of their high AChE activity, act as a biologic integrator of plasma input function during PET scanning, when regional metabolic rates of [(11)C]MP4A through AChE (k(3); an AChE index) are calculated by using Blomqvist's linear least squares analysis. Computer simulation studies showed that RLS analysis yielded k(3) with almost the same accuracy as the standard nonlinear least squares (NLS) analysis in brain regions with low (such as neocortex and hippocampus) and moderately high (thalamus) k(3) values. The authors then applied these methods to [(11) C]MP4A PET data in 12 healthy subjects and 26 patients with Alzheimer disease (AD) using the cerebellum as the reference region. There was a highly significant linear correlation in regional k(3) estimates between RLS and NLS analyses (456 cerebral regions, [RLS k(3) ] = 0.98 x [NLS k(3) ], r = 0.92, P < 0.001). Significant reductions were observed in k(3) estimates of frontal, temporal, parietal, occipital, and sensorimotor cerebral neocortices (P < 0.001, single-tailed t-test), and hippocampus (P = 0.012) in patients with AD as compared with controls when using RLS analysis. Mean reductions (19.6%) in these 6 regions by RLS were almost the same as those by NLS analysis (20.5%). The sensitivity of RLS analysis for detecting cortical regions with abnormally low k 3 in the 26 patients with AD (138 of 312 regions, 44%) was somewhat less than NLS analysis (52%), but was greater than shape analysis (33%), another method of [(11)C]MP4A kinetic analysis without blood sampling. The authors conclude that RLS analysis is practical and useful for routine analysis of clinical [(11)C]MP4A studies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11702050     DOI: 10.1097/00004647-200111000-00011

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  25 in total

1.  Clinical markers for identifying cholinergic deficits in Parkinson's disease.

Authors:  Martijn L T M Müller; Nicolaas I Bohnen; Vikas Kotagal; Peter J H Scott; Robert A Koeppe; Kirk A Frey; Roger L Albin
Journal:  Mov Disord       Date:  2014-11-12       Impact factor: 10.338

2.  Neuroimaging and clinical predictors of fatigue in Parkinson disease.

Authors:  Kelvin L Chou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2015-12-02       Impact factor: 4.891

3.  Peripheral neuropathy is associated with more frequent falls in Parkinson's disease.

Authors:  Mélanie L Beaulieu; Martijn L T M Müller; Nicolaas I Bohnen
Journal:  Parkinsonism Relat Disord       Date:  2018-04-03       Impact factor: 4.891

4.  Diabetes mellitus is independently associated with more severe cognitive impairment in Parkinson disease.

Authors:  Nicolaas I Bohnen; Vikas Kotagal; Martijn L T M Müller; Robert A Koeppe; Peter J H Scott; Roger L Albin; Kirk A Frey; Myria Petrou
Journal:  Parkinsonism Relat Disord       Date:  2014-10-15       Impact factor: 4.891

5.  Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study.

Authors:  Nicolaas I Bohnen; Kirk A Frey; Stephanie Studenski; Vikas Kotagal; Robert A Koeppe; Gregory M Constantine; Peter J H Scott; Roger L Albin; Martijn L T M Müller
Journal:  Mov Disord       Date:  2014-06-07       Impact factor: 10.338

6.  Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease.

Authors:  Martijn L T M Müller; Roger L Albin; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Kirk A Frey; Nicolaas I Bohnen
Journal:  Brain       Date:  2013-09-20       Impact factor: 13.501

7.  Mentally stimulating activities associate with better cognitive performance in Parkinson disease.

Authors:  Jeffrey L B Bohnen; Martijn L T M Müller; Jacob Haugen; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2017-07-19       Impact factor: 3.575

8.  Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease.

Authors:  Neha Shah; Kirk A Frey; Martijn L T M Müller; Myria Petrou; Vikas Kotagal; Robert A Koeppe; Peter J H Scott; Roger L Albin; Nicolaas I Bohnen
Journal:  Mov Disord       Date:  2015-09-18       Impact factor: 10.338

9.  Gender differences in cholinergic and dopaminergic deficits in Parkinson disease.

Authors:  Vikas Kotagal; Roger L Albin; Martijn L T M Müller; Robert A Koeppe; Kirk A Frey; Nicolaas I Bohnen
Journal:  J Neural Transm (Vienna)       Date:  2013-03-27       Impact factor: 3.575

10.  Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Vikas Kotagal; Robert A Koeppe; Michael A Kilbourn; Roger L Albin; Kirk A Frey
Journal:  Brain       Date:  2010-04-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.